New protein offers hope to AMD sufferers

Article

A protein, called Robo4, has been identified which appears to play an important role in the development of stable, working blood vessels.

A protein, called Robo4, has been identified which appears to play an important role in the development of stable, working blood vessels, reports a study published online ahead of print by Nature Medicine.

Dean Y Li and colleagues from the University of Utah activated the proteins in mice bred to mimic the effects of age-related macular degeneration (AMD) and diabetic retinopathy (DR) and found that blood vessel damage was prevented and, in some cases, even reversed.

Although this does not yet prove that the same principle will work in humans, the researchers believe that it does represent a major breakthrough, which could be harnessed to produce important drugs.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.